Veracyte Announces Receiving Of Coverage For Its Prosigna Breast Risk Of Recurrence Test For Its Technical Assessment Submission Through Palmetto GBA’s MolDX Program

Veracyte, Inc. (Nasdaq: VCYT) announced that its Prosigna Breast Risk of Recurrence test has received coverage through Palmetto GBA’s MolDX program, establishing a reimbursement path for eligible early-stage breast cancer patients. This coverage, effective August 19, 2026, applies to postmenopausal women with early-stage estrogen receptor positive breast cancer meeting specific Medicare criteria. The decision supports broader adoption of the test following its U.S. launch in June 2026.